Free Affidavit of Service - District Court of Delaware - Delaware

Case 1:07-cv-00765-SLR

Document 7

Filed 12/10/2007

Page 1 of 2

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE BOSTON SCIENTIFIC CORPORATION and BOSTON SCIENTIFIC SCIMED, INC., ) }
)

Plaintiffs, V.

Civil Action No. 07-765-SLR JURY TRIAL DEMANDED ) )
) )

JOHNSON & JOHNSON, INC. and CORDIS CORPORATION,
Defendants.

AFFIDAVIT OF NON-RESIDENCE OF JOHNSON & JOHNSON INC. PURSUANT TO 10 DEL. C. 3104
STATE OF DELAWARE ) )Ss.

COUNTY OF NEW CASTLE

)

BE IT REMEMBERED that on this 10`t' day of December, 2007, the deponent Karen E. Keller, personally appeared before me , a Notary Public for the State and County aforesaid, and deposed and stated as follows: 1. I am an attorney with the law firm of Young Conaway Stargatt & Taylor, LLP,

attorneys for the plaintiff in the above captioned matter. 2. The defendant, Johnson & Johnson, Inc. is a non-resident of the State of

Delaware, and on November 27, 2007 and all other times pertinent , was a non-resident of the State of Delaware . The last known available address of Johnson & Johnson , Inc. is One Johnson & Johnson Plaza , New Brunswick, New Jersey 08933. 3. On December 2, 2007, I caused to be mailed by registered mail an envelope to

Johnson & Johnson, Inc. at the address above. The envelope contained copies of a Notice in the

DB01:2492358 . 1

054604.1003

Case 1:07-cv-00765-SLR

Document 7

Filed 12/10/2007

Page 2 of 2

form attached hereto as Exhibit 1, and copies of the Summons and Complaint, attached hereto as Exhibit 2, to the last-known address listed in paragraph 2 of this Affidavit. Attached hereto as Exhibit 3 is the receipt of registered mail which was obtained at the Post Office upon mailing of the envelope. 4. On December 7, 2007,1 received from the United States Post Office the return

receipt showing delivery and acceptance by Johnson & Johnson, Inc. of the envelope. Pursuant to Local Rule 4.1(b), said return receipt is attached hereto as Exhibit 4.

Kare

Keller {94489

SWORN TO AND SUBSCRIBED before me, a Notary Public in and for the
State and County aforesaid, on the day and year first above written.

Notary Public My Commission Expires: -ac t

DB01:2492368.1

054604.1003

Case 1:07-cv-00765-SLR

Document 7-2

Filed 12/10/2007

Page 1 of 3

EXHIBIT 1

Case 1:07-cv-00765-SLR

Document 7-2

Filed 12/10/2007

Page 2 of 3

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE BOSTON SCIENTIFIC CORPORATION and BOSTON SCIENTIFIC SCIMED, INC.,

Plaintiffs,

V.
JOHNSON & JOHNSON, INC. and CORDIS CORPORATION, Defendants.

Civil Action No. 07-765 JURY TRIAL DEMANDED

NOTICE
TO: JOHNSON & JOHNSON, INC. One Johnson & Johnson Plaza New Brunswick, NJ 08933

PLEASE TAKE NOTICE that there has been served upon the Secretary of State of the State of Delaware the original of a Summons and Complaint, copies of which are attached hereto, in which you are named as a defendant in an action brought by Boston Scientific Corporation and Boston Scientific Scirned, Inc. Said Summons and Complaint were served upon the Secretary of State of the State of Delaware on November 27, 2007, and service of process was filed with the United States District Court for the District of Delaware on November 28, 2007. Under the provisions of 10 Del. C. § 3104, service of the original Summons and Complaint upon the Secretary of State as aforesaid is as effectual to all intents and purposes as if it had been made upon you personally within the State of Delaware.

npiru-7dRd09"A 3

(MAM 10M

Case 1:07-cv-00765-SLR

Document 7-2

Filed 12/10/2007

Page 3 of 3

Failure on your part to obey the command of the within writ could result in a default judgment being taken against you.

YOUNG CONAWAY STARGATT & TAYLOR, LLP

Josy`W. Ingersoll (#1088) Karen E. Keller (#4489) The Brandywine Building, 17'' Floor 1000 West Street Wilmington, DE 19801 j ingers oll@ycst. corn [email protected] (302) 571-6554

Of Counsel:
Richard L. Delucia. Paul M. Richter Michael K. Levy Jerry Canada KENYON & KENYON LLP One Broadway

a4ttorneysfor Plaintiffs Boston Scientific Corporation and Boston Scientific Scimed, Inc.

New York, NY 10004 (212) 425-7200

Dated: November 28, 2007

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 1 of 38

EXHIBIT 2 PART 1

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 2 of 38

AO 440 ( Rev. 10193) Summons in a Civil Action

United States District Court
DISTRICT OF BOSTON SCIENTIFIC CORPORATION and BOSTON SCIENTIFIC SCEVIED, INC.,
Plaintiffs,
V.

DELAWARE

SUMMONS IN A CIVIL CASE
CASE NUMBER:

JOHNSON & JOHNSON, INC. and CORDIS CORPORATION,
Defendants.

V 4o5

TO:

JOHNSON & JOHNSON, INC. c/o Secretary of State Division of Corporations John G. Townsend Bldg. 401 Federal Street, Suite 4 Dover, DE 19901

YOU ARE HEREBY SUMMONED and required to serve upon PLAINTIFF'S ATTORNEY ( name and address) Josy W. Ingersoll, Esquire Karen E. Keller, Esquire Young Conaway Stargatt & Taylor, LLP 1000 West Street, 17th Floor

P. 0. Box 391 Wilmington, DE 19899-0391
an answer to the complaint which is herewith served upon you, within 20 days after service of this summons upon you, exclusive of the day of service. If you fail to do so, judgment by default will be taken against you for the relief demanded in the complaint. You must also file your answer with the Clerk of this Court within a reasonable period of time after service.

DETER T. DALLE

NOV 2 7 2037

CLERK

DATE

(BY) DEPUTY CLERK

DB01:2484265.1

054604.1003

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 3 of 38

AO 440 (Rev 10193) Summons in a Civil Action

RETURN OF SERVICE Service of the Summons and Complaint was
made by me '

DATE TITLE 10
rf j /^ s [

NA

OF SERVER (PRINT)

Check one box below to indicate appropriate method of service 61 u
^

Served personally upon the defendant. Place where served : 51ca60Y-A 2 LZ ^,t 1L,uJr J r-Cl'
L1 ; Y .

Le copies thereof at the defendant's dwelling house or usual place of abode with a person of suitable age and discretion then residing therein . Name of person with whom the summons and complaint were left:

u

Returned unexecuted:

u

Other (specify):

STATEMENT OF SERVICE FEES
TRAVEL SERVICES DECLARATION OF SERVER I declare under penalty of perjury under the laws of the United States of America that the foregoing information contained in the Return of Service and Statement of Service Fees is true and correct. TOTAL

Executed on ^Aw
Date i r Signature of Server

Address of Server As to who may serve a summons see Rule 4 of the Federal Rules of Civil Procedure.
T t3nI . 'lAon-144 1 054604.1003

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 4 of 38

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

BOSTON SCIENTIFIC CORPORATION and BOSTON SCIENTIFIC SCIMED, INC.,

07 ° 765
Plaintiffs,
V.

Civil Action No.

JURY TRIAL DEMANDED

JOHNSON & JOHNSON, INC. and CORDIS CORPORATION,
Defendants.

COMPLAINT FOR DECLARATORY JUDGMENT OF PATENT INVALIDITY AND NONINFRINGEMENT

CD

Plaintiffs Boston Scientific Corporation and Boston Scientific Scimed, Inc. (collectively "BSC"), through their attorneys, bring this complaint against Defendants Johnson & Johnson, Inc. and Cordis Corporation (collectively "J&J") and requests a jury trial on all issues so triable. BSC alleges as follows, upon knowledge with respect to itself and its own acts, and upon information and belief as to the circumstances and facts of others:

NATURE OF THE ACTION
1. This is an action for a declaratory judgment that United States Patent No.

7,300,562 entitled "Drug/Drug Delivery Systems for the Prevention and Treatment of Vascular Disease" (the "Falotico '662 patent") is invalid and not infringed by BSC. The Falotico '652 patent is attached as Exhibit A.

1)1301:2484242.1

054604.1003

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 5 of 38

THE PARTIES
2. Plaintiff Boston Scientific Corporation is a corporation organized under the laws

of the State of Delaware, having its principal place of business at One Boston Scientific Place, Natick, Massachusetts 01760. 3. Plaintiff Boston Scientific Scimed, Inc. is a corporation organized under the laws

of the State of Minnesota, having its principle place of business at One Scimed Place, Maple Grove, Minnesota 55311. 4. Upon information and belief, Defendant Johnson & Johnson, Inc. is a corporation

organized under the laws of the State of New Jersey and has a principal place of business at One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933. 5. Upon information and belief, Defendant Cordis Corporation ("Cordis") is a

corporation organized under the laws of the State of Florida and has a principal place of business in Miami Lakes, Florida. Cordis is a subsidiary of Johnson & Johnson, Inc.

JURISDICTION AND VENUE
6. sect. ). 7. This Court has jurisdiction over the subject matter of all causes of action herein This action arises under the Patent Laws of the United States (35 U.S.C. § 1, et

pursuant to 28 U.S.C. §§ 1331, 1338 (a), 2201 and 2202. 8. On information and belief, J&J has systematic and continuous contacts in this

judicial district. 9. On information and belief, J&J regularly avails itself of the benefits of this

judicial district, including the jurisdiction of the courts.

2 DBO E :2484292. 1 054604.1003

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 6 of 38

10,
district.

On information and belief, J&J regularly transacts business within this judicial

11.

On information and belief, J&J regularly sells products in this judicial district.

J&J derives substantial revenues from sales in this district. 12. 13. and 1400(b). This Court has personal jurisdiction, general and specific, over J&J. Venue in this judicial district is proper pursuant to 28 U.S.C. §§ 1391(b) and (c)

BACKGROUND 14. BSC is a world renowned leader in the development of intravascular stents used

to treat coronary artery disease. 15_ J&J and, in particular, Cordis, directly compete with BSC in the field of

intravascular stents used to treat coronary artery disease. 16. J&J has a well-known history of suing competitors, including BSC, in the field of

intravascular stents for patent infringement. Within the past several years, J&J and/or Cordis have sued BSC in this Court, alleging patent infringement in cases involving intravascular stents used to treat coronary artery disease. BSC has also brought suits for patent infringement against J&J within this judicial district. 17. Pursuant to an agreement between BSC and Abbott Laboratories ("Abbott"), BSC

is presently selling the PROMUSTM Everolimus-Eluting Coronary Stent System. ("PROMUS") in Europe and other countries outside the United States. The PROMUS stent is a private-labeled XIENCETM V Everolimus Eluting Coronary Stent System ("XIENCE V") which is manufactured for BSC by Abbott in the United States. The PROMUS stent is an intravascular scent used to

3 DB012484292 . 1 054604.1003

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 7 of 38

treat coronary artery disease. It advantageously releases a drug designed to diminish reblocking (restenosis) of the patient's blood vessel into which the stent has been inserted. 18. The PROMUS stent received CE Mark approval in October 2006, which allows

BSC to distribute PROWS in 27 countries of the European Economic Area. Since that time, BSC has been taking title to the PROWS scent from Abbott in the United States and then exporting those stents to the European market. BSC intends to begin selling its PROWS stent in the United States in 2008. 19. In 2006, BSC purchased Guidant Corporation ("Guidant"). As part of the

agreement governing the Guidant acquisition, Guidant separately sold the rights to its everolimus-eluting scent product to Abbott. BSC separately entered into an agreement with Abbott that permits BSC to sell (under the designation "PROMUS") the everolimus-eluting stents manufactured by Abbott (which Abbott sells on its own as its "XIENCE V" stent). 20. Abbott currently manufactures and sells its own everolimus-eluting stent, the

XIENCE V stent, which is the same product as BSC's PROMUS stent, and BSC has made a substantial investment in the PROWS stent. 21. On May 15, 2007, Cordis filed a Complaint against Abbott in the United States

District Court for the District of New Jersey (Civil Action No. 07-2265), alleging infringement of U.S. Patent No. 7,217,286 (the "Falotico '286 patent" or alternatively, the `"7286 patent"). On May 29, 2007, Cordis filed a Complaint against Abbott in the United States District Court for the District of New Jersey (Civil Action No. 07-2477), alleging infringement of U.S. Patent No. 7,223,286 (the "Wright '286 patent" or alternatively, the "°3286 patent"). On June 12, 2007, Cordis fled a Complaint against Abbott in the United States District Court for the District of New Jersey (Civil Action No. 07-2728), alleging infringement of U.S. Patent No. 7,229,473 (the

4 DB01:248429 ? t

054604.1003

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 8 of 38

"Wright '473 patent"). Collectively, these three Cordis patents are referred to as "the Asserted Cordis Patents." 22. During the prosecution of each of the Asserted Cordis Patents, Cordis separately

petitioned the United States Patent and Trademark Office for expedited consideration in view of perceived patent infringement in connection with the XIENCE V scent. Upon issuance of these three patents, Cordis promptly asserted the new patents against Abbott. Exactly the same circumstances exist with regard to the Falotico '662 patent: Cordis likewise petitioned for expedited Patent Office review of the application that led to the Falotico '662 patent based, again, on perceived infringement by the XIENCE V stent. The petition of August 7, 2006 is attached as Exhibit B. 23. Cordis' recent pattern of promptly asserting its new patents, and in particular

those patents issuing from an expedited Patent Office evaluation demanded by Cordis because of alleged infringement, has created a present substantial controversy between J&J and BSC concerning the PROMUS stent. J&J, through Cordis, has asserted rights under related patents against the same product as the PROMUS stent, and the alleged infringement of the Asserted Cordis Patents has created an apprehension that Cordis will sue BSC for alleged infringement of the Falotlco '662 patent.

RELATED CASES PENDING IN THE DISTRICT OF DELAWARE
24. There are now five cases pending in the District of Delaware that are related to

the instant case, as set forth in the below paragraphs. 25. On September 29, 2006, Abbott filed a declaratory judgment action against J&J,

alleging that other Cordis-owned patents - U.S. Patent Nos. 6,585,764 (the "'764 patent"), 6,776,796 (the "'796 patent"), and 6,808,536 (the `536 patent") -- are invalid and not infringed

5 DSd 1:2484292 . 1 754604. 003

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 9 of 38

by Abbott' s manufacture and/or use of the XIENCE V stent in the Unites States. (See Ex. C, the complaint in Civil Action No. 06-613-SLR).' Although on August 8, 2007 , Cordis granted Abbott a covenant not to sue on those patents, that action remains active in view of pending motions to amend the complaint, as explained below. 26. On May 15, 2007, Abbott filed a declaratory judgment action against Cordis in

the United States District Court for the District of Delaware relating to U.S. Patent No. 7,217,286 (the "Falotico '286 patent"). (See Ex. D, the complaint in Civil Action No. 07-259-SLR). Abbott alleges in its May 15 complaint that the Falotico '286 patent is invalid and not infringed by Abbott' s manufacture and/or use of the XIENCE V stent in the Unites States. (Id. at p. 17). Abbott's declaratory judgment action against the Falotico '286 patent , which is currently pending in this judicial district , is the first filed action concerning the Falotico '286 patent. Also on May 15, 2007, Abbott filed a motion for leave to file a supplemental complaint or in the alternative to consolidate related cases in Civil Action No. 06-613-SLR pending before the United States District Court for the District of Delaware. (See Ex. E, Abbott' s motion for leave to file a supplemental complaint or consolidate related cases ). Abbott's motion requests leave to file a supplemental complaint to add a claim for declaratory judgment of invalidity and noninfringement of the Falotico '286 patent. (Id. at p. 2). 27. On May 25, 2007, BSC filed a declaratory j udgment action against Cordis in the

United States District Court for the District of Delaware relating to the Falotico '286 patent. (See Ex. F, the complaint in Civil Action No. 07-333-SLR). BSC asserts in that May 25

The exhibits originally filed with Exhibits C-L herein have not been attached . Exhibits C-K correspond to Exhibits C- K filed with the compliant in Civil Action No. 07-409-SLR and Exhibit L is the complaint in Civil Action No. 07-409-SLR. Should the Court require a copy of these exhibits, Plaintiffs are available to do so.

6
QBO 1 :24 $4292 . 1

054604.1003

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 10 of 38

complaint that the Falotico '286 patent is invalid and not infringed by BBC's above-recited activities regarding the PROMUS stent. (Id. at p. 6). 28. On May 29, 2007, Abbott filed a supplemental motion for leave to file a

supplemental complaint or in the alternative to consolidate related cases in Civil Action No. 06613-SLR pending before the United States District Court for the District of Delaware. (See Ex. G, Abbott's motion for leave to file a supplemental complaint or to consolidate related cases). Also on May 29, 2007, Abbott filed a motion for leave to file a supplemental complaint in Civil Action No. 07-259-SLR pending before the United States District Court for the District of Delaware. (See Ex. H, Abbott's supplemental motion for leave to file a supplemental complaint). Abbott's motions request leave to file supplemental complaints to add claims for declaratory judgment of invalidity and noninfringement of U.S. Patent No. 7,223,286 (the "Wright '286 patent"). (Ex. G at p. 1; Ex. H at p. 1). 29. On June 1, 2007, BSC filed a declaratory judgment action against J&J in the

United States District Court for the District of Delaware relating to the Wright '286 patent. (See Ex. I, the complaint in Civil Action No. 07-348-SLR). BSC asserts in its June 1 complaint that the Wright '286 patent is invalid and not infringed by BSC's above-recited activities regarding the PROWS scent. (Id. at p. 7). 30. On June 12, 2007, Abbott filed a second supplemental motion for leave to file a

supplemental complaint or in the alternative to consolidate related cases in Civil Action No. 06613-SLR pending before the United States District Court for the District of Delaware. (See Ex. J, Abbott's second supplemental motion for leave to file a supplemental complaint or to consolidate related cases). Also on June 12, 2007, Abbott filed a supplemental motion for leave to file a supplemental complaint in Civil Action No. 07-259-SLR pending before the United

7 DBOI:2484292 . 1
054604.1003

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 11 of 38

States District Court for the District of Delaware. (See Ex. K, Abbott's supplemental motion for leave to file a supplemental complaint). Abbott's motions request leave to file supplemental complaints to add claims of invalidity and noninfringement of U.S. Patent No. 7,229,473 (identified as the "Wright '473 patent"). (Ex. J at p. 1; Ex. K at p. 1). 31. On June 22, 2007, BSC filed a declaratory judgment action against J&J in the

United States District Court for the District of Delaware relating to the Wright '473 patent. (See Ex. L, the complaint in Civil Action No. 07-409-SLR). BSC asserts in its June 22 complaint that the Wright '473 patent is invalid and not infringed by BSC's above-recited activities regarding the PROMUS stent. (Id. at p. 8). 32. The instant action by BSC against J&J is related to Abbott's September 29, 2006

action because at least the Falotico '796 patent is part of the same patent family as the Falotico '662 patent, the prior art to both patents is related, and the products at issue in the September 29, 2006 action (Abbott's XIENCE V) and this action (BSC's PROMUS) are related. Also, as discussed above, Abbott has also recently filed motions to amend its complaint in the September 29, 2006 action to include the Falotico '286 patent, the Wright '286 patent, and the Wright '473 patent or, in the alternative, consolidate its September 29, 2006, May 15, May 29, and June 12 actions. 33. The instant action by BSC against J&J is related to Abbott's May 15 complaint

and supplemental complaint and BSC's May 25 complaint on the Falotico '286 patent, Abbott's May 29 supplemental complaints and BSC's June 1 complaint on the Wright '286 patent, and BSC's June 22 complaint on the Wright '473 patent, because the patents involved all have claims purporting to cover similar subject matter, the prior art to the those patents is related, and the products of the declaratory judgment plaintiffs, XIENCE V (Abbott) and PROMUS (BSC), are

8
DB01:2484292.1 054604,1003

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 12 of 38

related. Essentially identical Scheduling Orders have been entered in Abbott' s declaratory judgment case (Civil Action No. 06-613-SLR, D.I. 85) and BSC's declaratory judgment cases (Civil Action No. 07-333-SLR, D.I. 19; Civil Action No. 07-348-SLR, D.T. 17; Civil Action No. 07-409-SLR, D. I. 18).

COUNTI INVALIDITY AND NONINFRINGEMENT OF U.S. PATENT NO. 7 ,300 ,662
34. BSC repeats and realleges each and every allegation contained in paragraphs 1-33

of this Complaint as though fully set forth herein. 35. Each of the claims in the Falotico '662 patent is invalid for failure to comply with

one or more of the requirements of Title 35, United States Code, including, but not limited to, 35 U.S.C. §§ 102,103 and 112. 36. The PROMUS stent does not infringe any valid claim of the Falotico '662 patent.

PRAYER FOR RELIEF
WHEREFORE , BSC prays that this Court enter j udgment as follows, ordering that: (a) (b) Each and every claim of U.S. Patent No. 7,300,662 is invalid; Plaintiffs are not liable for directly , contributorily or inducing infringement of any

claim of U.S. Patent No . 7,300,662; (c) Defendants and their officers , agents, employees , representatives , counsel and all

persons i n active concert or participation with any of them, directly or indirectly , be enjoined from threatening or charging i nfringement of, or instituting any action for infringement of U.S. Patent No . 7,300,662 against Plaintiffs, its suppliers , customers , distributors or users of its products;

9
DB01:2484292 . 1

054504.1003

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 13 of 38

(d)

Defendants pay to Plaintiffs the costs and reasonable attorney's fees incurred by

Plaintiffs in this action; and (e) proper. Plaintiffs be granted such other and further relief as this Court deems just and

DEMAND FOR JURY TRIAL
Plaintiffs demand a trial by jury on all issues so triable.

YOUNG CONAWAY STARGATT & TAYLOR, LLP

Josy W. Ingersoll (91088 Karen E. Keller (44489)
The Brandywine Building, 1701 Floor 1000 West Street Wilmington, DE 19801 jingersoll @ycst.com [email protected] (302) 571-6554

Of Counsel.Richard L. Delucia Paul M . Richter Michael K. Levy Terry Canada KENYON & KENYON LLP One Broadway New York, NY 10004 (212) 425-7200

Attorneys for Plaintiffs Boston Scientific Corporation afzd Boston Scientific Schned, Inc.

Dated: November 27, 2007

10 DB01:24W92. l 054604.3003

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 14 of 38

EXHIBIT A

Case 1:07-cv-00765-SLR

Document 7-3

I W I III I YN I I I OIn IIIIIIIV1111 11^1191101111
US 7,300,662 B2 (1a) Patent No.: *Nov. 27, 2007 (45) Date of Patent:
Field of Classification Search ........ 4241422-426; 623/1.42-1.48 See application file for complete search history. References Cited U.S. PATENT DOCUMENTS
861,659 A 3,051,677 A 3,279,996 A 3,526.005 A 3,599,641 A 711907 811962 1011966 9/1970 8!1971

Filed 12/10/2007

Page 15 of 38

(12) United States Patent
Falotico et al.
(54) DRUG/DRUG DELIVERY SYSTEMS FOR THE PREVENTION AND TREATMENT OF VASCULAR DISEASE Inventors: Robert Falotico , Belle Mead, NJ (US); Gregory A. Kopia , Hillsborough, NJ (US); Gerard H. Llanos, Stewartsville, NJ (US) Assignee: Cordis Corporation , Miami Lakes, FL (US)
Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 503 days.

(58)

(75)

(56)

(73)

Johnston ..................... 4641147 Rexford ...................... 522/156 Long et al .................. 424/424 Bolros .................... 623111.11 Sheridan ..................... 6041256

(Continued) FOREIGN PATENT DOCUMENTS
DE 3205942 Al 911983

This patent is subject to a terminal disclaimer. (21) (22) (65) Appl. No.: 101829,074 Filed: Apt. 21, 2004 Prior Publication Data US 2004/0260268 Al Dec. 23, 2004

(Continued) OTHER PUBLICATIONS
Boston Scientific, "Measuring DES Efficacy," www.taxus- stent. comlasa/effiicacy.html, pp. 1.3, copyright 2006.' (Continued) Primary Examiner-Sbaron E. Kennedy

Related U.S. Application Data (63) Continuation-in-part of application No. 09/850,293, filed on May 7, 2001, now abandoned, which is a continuation-in-part of application No. 09/575,480, filed on May 19, 2000. Provisional application No. 601263,979, filed on Jan. 25, 2001, provisional application No. 601263,806, filed on Jan. 24, 2001, provisional application No. 601262,614, filed on Jan. 18, 2001, provisional application No. 601262,461, filed on Jan. 18, 2001, provisional application No. 601204,417, filed on May 12, 2000. Int. Cl. (2006.01) A61F 2100 (2006.01) A61F 2106 U.S. Cl...................... 424/424-,62311.42; 62311.45

(74) Attorney, Agent, or Finn-Woodcock Washburn LLP (57) ABSTRACT

(60)

(51)

A drug and drug delivery system may be utilized in the treatment of vascular disease. A local delivery system is coated with rapamycin or other suitable drug,, agent or compound and delivered intraluntinally for the treatment and prevention of neointimal hyperplasia following percutaneous transluminal coronary angiogzaphy. The local delivery of the drugs or agents provides for increased effectiveness and lower systemic toxicity. 25 Claims, 2 Drawing Sheets

(52)

104

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 16 of 38

US 7,300,662 B2
Page 2
5,047,020 A 5,049,132 A 5,049.403 A 5,053,048 A 5,059,166 A 5,061,275 A 5,061,750 A 5,064,435 A 5,092,877 A 5,102,417 A 5,104,404 A 5,116,365 A 5,122,154 A 5,131,908 A 5,133,732 A 5,134,192 A 5,135,536 A 5,163,952 A 5,163,958 A 5,171,217 A 5,171,262 A 5,176,660 A 5,176,972 A 5,178,618 A 5,180,366 A 5,182,317 A 5,185,408 A 5,192,307 A 5,195,984 A 5,202,332 A 5,213,576 A 5,213,898 A 5,217,483 A 5,222,971 A 5,226,913 A 5,234,456 A 5,246,445 A 5,258,020 A 5,258,021 A 5,262,451 A 5,266,073 A 5,272,012 A 4,733,665 A 5,275,622 A 5,282,823 A 5,282,824 A 5,283,257 A 5,288,711 A 5,290,305 A 5,292,331 A 5,292,802 A 5,304,121 A 5,304,200 A 5,306,250 A 5,308,862 A 5,308,889 A 5,314,444 A 5,314,472 A 5,326,471 A 5,334,301 A 5,336,518 A 5,338,770 A 5,342,348 A 5,342,387 A 5,342,621 A 5,354,257 A 5,354,308 A 5,356,433 A 5,366,504 A 5,368,566 A 5,370,683 A 5,370,691 A 5,375,612 A 911991 Hsu ........................... 6041266 911991 Shaffer ct al. 911991 Larm et al ................... 42712.1 10/1991 Pinchuk 1011991 Fischell ct al . ................ 60013 1011991 Wallsten at al. 1011991 Fcijen at al. 1111991 Potter 311992 Pinchuk 411992 Palmaz 411992 Wot1T 511992 Hillstead 611992 Rhodes 711992 Dardik at al. 711992 WI-tor 711992 Feijen el al. 8/1992 Hillstead 1111992 Froix 1111992 Pincbuk 1211992 March ct al. ............... 6041507 1211992 MacGregor 111993 Truckai .......430/14 ..... 111993 Bloom at al . 111993 Kandarpa 111993 Woods 111993 Winters et al. 2J1993 Tang at al. 311993 Wall 311993 Schalz 411993 Hughes. at al ............... 5141291 511993 Abiuso ct al. 511993 Larm at al. ... .............. 4281422 611993 Tower 611993 Willard at al. 711993 Pinchuk 811993 Silvestrini 9/1993 Yachia at al. 1111993 Froix 11/ 1993 Duran 1111993 Winters at al. 1111993 Wall 12/1993 Opolski ................... 4281423.1 111994 Palmaz ....................... 6061108 171994 Lazarus at al. 211994 Schwartz el al. 211994 Gianturco 211994 Gregory et al. 211994 Mitchell at al. 311994 Inoue 311994 Boneau 311994 Rhea at al, 411994 Sahatjian 411994 Spaulding 411994 March at al. 5!1994 Ohlstein 511994 Rhea et al. 511994 Giamutco 511994 Fontaine 711994 Slepian 811994 Heinke at al. 811994 Pallassana et al. 811994 Winters et al, 811994 Kaplan 8/1994 Surnmers 811994 Eury 10/1994 Roubin ct it. 1011994 Simon at it, 1011994 Rowland at al. 1111994 Andersen at al. 1111994 Crocker 12/1994 Fontaine 1211994 Samson 1211994 Cottenceau et al.

U.S. PATENT DOCUMENTS
3,657,744 A 3,744,596 A 3,779,805 A 3,929,992 A 3,932,627 A 3,948,254 A 3,952,334 A 3,968,800 A 4,069,307 A 4,076,285 A 4,292,965 A 4,299,226 A 4,300,244 A 4,312,920 A 4,321,711 A 4,323,071 A 4,390,599 A 4,413,359 A 4,423,183 A 4,441,216 A 4,503,569 A 4,512,338 A 4,550,447 A 4,553,545 A 4,560,374 A 4,562,596 A 4,565,740 A 4,580,568 A 4,613,665 A 4,642,111 A 4,655,771 A 4,656,083 A 4,676,241 A 4,678,466 A 4,687,482 A 4,689,046 A 4,731,054 A 4,733,665 A 4,739,762 A 4,740 207 A 4,749,585 A 4,753,652 A 4,760,849 A 4,768,507 A 4,776,337 A 4,786,500 A 4,787,899 A 4,800,882 A 4,810,784 A 4,856,516 A 4,871,357 A 4,872,867 A 4,876,109 A 4,886,062 A 4,907,336 A 4,916,193 A 4,954,126 A 4,969,458 A 4,990,131 A 4,990,155 A 4,994,071 A 4,994,298 A 4,998,923 A 5,015,253 A 5,019,090 A 5,019,096 A 5,029,877 A 5,034,265 A 5,035,706 A 5,041,100 A 5,041,126 A 411972 Ersek 711973 Sander ....................... 1881213 12/1973 Alsberg ...................... 427/105 12/1975 Sehgal ct al ................ 4241122 111976 Margraf 411976 Zaffaroni .................... 1281833 411976 Bokros ct al. ........... 623111.11 7!1976 ViWi ......................... 6061198 111978 Higucbi et al. ............. 4241432 211978 Martinez .................... 2851332 3011981 Nash ct al. 11/1981 Banka ........................ 604!509 1111981 Bokros ...................... 62311.13 111982 Pierce et al .............. 4281425.5 311982 Mano ........................ 62311.43 4/1982 Simpson ct al . ............ 6061194 611983 Broyles ...................... 4281597 1111983 Akiy,'tma et al. ........ 623/23.72 172/1983 Close ......................... 5241546 411984 lonescu ct al. 311985 Dotter 411985 Balko et al ................. 6061108 1111985 Seiler, Jr. at al........... 62311.32 1111985 Maass et al. 1211985 Hammcrslag ............... 604/509 1/1986 Kronberg ................... 62311.32 111996 Golander ct al. ........... 4281409 411986 Gianturco 911986 Larm 211987 Sakunoto at a1. .......... 4241492 411987 Wallsten 411987 Hoffman at al ............. 4421123 611987 Webb at al. ........... 129/207.14 711987 Rosenwald ................. 4241427 811987 Hanson ..................... 62311.49 811987 Bokms ...................... 623/2.31 3/1988 Bitlcter et al ............ 604193.01 3/1988 Palmaz 411988 Palmaz 411988 Kreamer .................... 62311.15 611988 Greco at al. ............. 4281422 611988 Langer at al, ............. 62311.42 V1988 Kropf ......................... 606/191 911988 Fischell ct d . ............ 6231.1 1011988 Pal maz 1111988 Wong ......................... 4241422 1111988 Lazarus ..................... 62311.11 111989 Gianturco 536120 311989 Larm 811989 Hillstcad 1011989 Hsu et al .................... 604/266 1011989 lob 1011989 Mayer at al . ............... 604/269 12/1989 Wiktor 311990 Gianturco 411990 Tang at al. 913990 Wallsten 1111990 Wiktor 211991 Dardik 211991 Wilkoff 211991 MacGregor 211991 Yasuda ....................... 4271490 311991 Samson at al. ............. 606/194 511991 MacGregor 5/1991 Pinehuk ..................... 62311.15 511991 Fox, Jr. et al . ............... 600136 711991 Fcdeli at al ................. 2771354 7/1991 Hallman et al . ............ 4421126 711991 Gianturcc 811991 Rowland et al. 811991 Gianturco

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 17 of 38

US 7,300,662 B2
Page 3
1211994 Duran 111995 Smith at al. ................ 4241473 111995 Fearnot at at. 111995 Palmaz 1/1995 Jung at al. - ........... 604/103.04 111995 Scott at al. 211995 Chuter 2!1995 Tower 211995 Skowicki at al............ 5401456 211995 Yoe at al. 311995 Simon at al. 311995 Marin at al. 3!1995 Hanson ...................... 4241423 411995 Solar 4/1995 Cragg 411995 Narayanan et al. 511995 Peters 511995 Lee et al. 511995 Hsu at al ................. 424018.27 511995 Narciso, Jr. 6!995 Fontaine 6!1995 Lau 611995 Williams 7!1995 Keogh 711995 Narciso 811995 Barry 811995 Khosravi at al. SI1995 Wang at al. 8!1995 Dodge at al. 811995 Bury 811995 Mann at al. 811995 Schwartz at al. 8/1995 Fontaine 811995 Sigwart 911995 Heimus at al. 911995 Schmaltz at al. 911995 Pinchasik at al. 911995 Dayton 1111995 Busccmi at al. 1111995 Friesen at at . .............. 2101640 1111995 Berg at al. 1211995 Myler at al. -- ............ 606!108 111996 Narayanan 311996 Sgro 311996 Buscemi at al. 411996 Molnar-Kimber at at. .. 5141291 411996 Dinh ct al. 411996 Domb et al ................. 6041265 5!1996 Morris at al. 511996 Morris at A ............... 514/378 611996 Hanson at al. 611996 Fontaine et al. 811996 Wolff at al. 911996 Buscemi at al. 911996 Dinh et al. 911996 Takahashi 911996 Lam 911996 Nelson at al . .............. 5141291 1011996 Lambert 1011996 Morris et al. 1011996 Helmus at al. 1011996 Lam 1011996 Martinson at al........... 4241423 1011996 Helmus at al . ............. 4241426 11/1996 Crocker ................. 6041103.01 1111996 Dinh at al. 1111996 Regunathan at at. 1111996 Pinchuk ..................... 62311.15 11!1996 Dayton 1211996 Bianco at al. 12/I996 Bianco at al. 111997 Narayanan ct al. 111997 Orth at al. 5,591,224 A 5,591,227 A 5,599,352 A 5,603,722 A 5,604,283 A 5,605,696 A 5,607,463 A 5,607,475 A 5,609,629 A 5,616,608 A 5,620,984 A 5,621,102 A 5,622,975 A 5,624,411 A 5,628,785 A 5,629,077 A 5,629,315 A 5,632,763 A 5,632,771 A 5,632,776 A 5,632,840 A 5,635,201 A 5,637,113 A 5,643,312 A 5,643,939 A 5,646,160 A 5,648,357 A 5,649,952 A 5,649,977 A 5,651,174 A 5,652,243 A 5,653,747 A 5,653,992 A 5,662,609 A 5,665,591 A 5,665,728 A 5,667,764 A 5,669,924 A 5,670,506 A 5,672,638 A 5,674,242 A 5,679,400 A 5,679,659 A 5,684,061 A 5,691,311 A 5,693,085 A 5,697,967 A 5,697,971 A 5,700,286 A 5,707,385 A 5,709,874 A 5,713,949 A 5,716,981 A 5,725,549 A 5,725,567 A 5,728,150 A 5,728,420 A 5,731,326 A 5,733,327 A 5,733,920 A 5,733,925 A 5,735,897 A 5,739,138 A 5,755,734 A 5,755,772 A 5,759,205 A 5,769,883 A 5,776,184 A 5,780,462 A 5,780,476 A 5,782,908 A 5,788,979 A 5,792,106 A 111997 Schwartz at al. 111997 Dinh at al. 2JI997 Dinh at al. 2/1997 Phan at al. 211997 1Vada at al . ................ 5241236 211997 Eury at a1. 311997 Schwartz at al. 311997 Cahalan at al. 311997 Feamot et al. 411997 Kinsella at al .............. 514/449 4/1997 Bianco at al. 411997 Bianco et al. 4/1997 Singh at al. 411997 Tuch 5/1997 Schwartz at al. 5/1997 Turnlund at al. 511997 Bianco et al. 511997 Cilastra 511997 Boatman at al............ 623/1.15 511997 Kurumatani at a1......... 4241423 511997 Campbell 611997 Fabo ................... ... 4241443 611997 Tartaglia at al. 711997 Fischelt at al. 711997 Ohlstein 7/1997 Morris at al. 711997 Bianco at al. 711997 Lam 711997 Campbell 7/1997 Schwartz at al. 711997 Bianco at al. 8/1997 Dercume ................... 62311.54 811997 Bczwada at al. 911997 Slepian 911997 Sonenshein at al. ........ 435/375 911997 Morris at al. 911997 Kopia at al, .- ........... 424/1.45 911997 Shaknovich 9/1997 Leigh at al. 9/1997 Verhoeven at al. ......... 5231112 1011997 Phan at a1 . ................. 6061198 1011997 Tuch 1011997 Verhoeven at al. 1111997 Ohnishi at al . ............. 5231114 1111997 Maraganorc at al, ......... 514/12 1211997 Buirge at at. 1211997 Dinh at al. 1211997 Fischell at al. 1211997 Tartaglia at al. 1/1998 Williams 1/1998 Hanson el al. 211998 Jayaraman ................. 62311.12 211998 Hunter at al . ._ ...... .... 5141449 311998 Lam 311998 Wolff at al. 3/1998 McDonald et at, 311998 Keogh 311998 Hart et al. 311998 Igaki at al. 311998 Manson at al. 311998 Kunz al al. 411998 Buirge 411998 Bianco at al. 511998 Richter at al. 511998 Evans at al ................. 128/898 611998 Valentini ....................4331173 611998 Buscemi ct al. 7/1998 Tuch 711998 Lee at al . ................... 5141183 711998 Underiner ct al. 7/1998 Cahalan al al. 8/1998 Alt 811998 Mischa .................. 604/103.01

5,376,112 A 5,376,475 A 5,380,299 A 5,382,261 A 5,383,853 A 5,383,928 A 5,387,235 A 5,389,106 A 5,391,730 A 5,393,772 A 5,395,390 A 5,397,355 A 5,399,352 A 5,403,341 A 5,405,377 A 5,409,696 A 5,411,549 A 5,415,619 A 5,417,969 A 5,419,760 A D359,802 S 5,421,955 A 5,423,885 A 5,429,618 A 5,429,634 A 5,439,446 A 5,441,515 A 5,441,516 A 5,441,947 A 5,443,458 A 5,443,477 A 5,443,496 A 5,443,498 A 5,443,500 A 5,447,724 A 5,449,372 A 5,449,373 A 5,449,382 A 5,464,450 A 5,464,540 A 5,464,650 A 5,474,563 A 5,486,357 A 5,496,365 A 5,500,013 A 5,504,091 A 5,510,077 A 5,512,055 A 5,516,781 A 5,519,042 A 5,523,092 A 5,527,354 A 5,545,208 A 5,551,954 A 5,554,182 A 5,554,954 A 5,556,413 A 5,559,122 A 5,562,922 A 5,563,146 A 5,569,197 A 5,569,295 A 5,569,462 A 5,569,463 A 5,571,089 A 5,571,166 A 5,574,059 A 5,575,818 A 5,578,075 A 5,580,873 A 5,580,874 A 5,591,140 A 5,591,197 A

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 18 of 38

US 7,300,652 S2
Page 4
5,792,772 A S,798,372 A 5,799,384 A 5,800,507 A 5,800,508 A 5,807,861 A 5,811,447 A 5,820,917 A 5,820,918 A 5,824,048 A 5,824,049 A 5,827,587 A 5,833,651 A 5,837,008 A 5,837,313 A 5,843,120 A 5,843,166 A 5,843,172 A 5,849,034 A 5,851,217 A 5,851,231 A 5,858,990 A 5,861,027 A 5,865,814 A 5,871,535 A 5,873,904 A 5,876,433 A 5,877,224 A 5,879,697 A 5,882,335 A 5,891,108 A 5,893,840 A 5,897,911 A 5,900,246 A 5,902,266 A 5,912,253 A 5,916,910 A 5,922,393 A 5,922,730 A 5,932,243 A 5,932,299 A 5,932,5S0 A 5,951,586 A 5,957,971 A 5,968,091 A 5,972,027 A 5,976,534 A 5,977,163 A 5,980,553 A 5,980,566 A 5,980,972 A 5,981,568 A 5,985,307 A 5,997,468 A 6,004,346 A 6,015,432 A 6,015,815 A 6,039,721 A 6,059,813 A 6,071,305 A 6,074,659 A 6,080,190 A 6,096,070 A 6,120,536 A 6,120,847 A 6,136,798 A 6,140,127 A 6,146,358 A 6,153,252 A 6,159,488 A 6,171,232 BI 6,171,609 B 6,177,272 BI 8/1998 Bianco ct al. 811998 Davies et al. 911998 Schwartz at al. 911998 Schwartz 911998 Goicoechea ct al. 911998 Klein el al. 911998 Kunz at M. 1011998 Tucb 1011998 Ronan et al. 1011998 Tuch 1011998 Ragheb at al. 1011998 Fukusbi ..................... 428136.6 1111998 Donovan et al. 11/1998 Berg at al. 1111998 Ding et al. 1211998 Israel at al ................. 62311.15 1211998 Lentz el al. ............... 62311.13 1211998 Yan 1211998 Schwartz 1211998 Wolff ct al. 1211998 Wolff cc al. 111999 Walsh 111999 Trapp 211999 Tuch 211999 Wolff et al. 2/1999 Ragheb et al. 311999 Lunn 311999 Brocchini at al. ....... 5141772.2 311999 Ding cc al. 311999 Leona at al. 4/1999 Leona at al. 411999 Hull et al . ............. 6041103.02 411999 LocEller ..................... 427/2.25 511999 Lambert 511999 Leone ct al. 611999 Cottens ct al, . ............. 5141291 611999 Lai ............................ 5141423 711999 Jayara nan .. ................ 427/2.3 711999 Hu ct al. .................... 5141291 811999 Frickcr et al. .............. 4241450 811999 Katoot .......................4271508 8!1999 Levitzk at al .............. 181/152 911999 Berg et al. 911999 Schwartz 1011999 Pinchuk et al ............. 62311.16 1011999 Johnson 1111999 Hart et al. 1111999 Li et al. 1111999 Gray ct al. 1111999 Alt et al. 11/1999 Ding 11/1999 Kunz et al. 11/1999 Hanson et al. 12/1999 Wolff et al. 1211999 Wolifct al. 112000 Rakes ct al ................ 62311.13 112000 Mollison .................... 5141291 312000 Johnson ct al. 512000 Vrba et al. 612000 Brown et al. 612000 Kunz ct al. 612000 Schwartz 812000 Ragheb ct al. 912000 Dioge et al. 9/2000 Yang ct al, ................. 4271335 1012000 Cody ct al. 1012000 Sprague 11/2000 Rowe 1112000 Hossainy et al. 1212000 Nagicr et al . . ........ ..... 4241423 112001 Papandreou et al. 112001 Kunz 1/2001 Nabel ct al. 6,179,817 BI 6,187,757 B1 6,193,746 131 6,214,901 131 6,225,346 B1 6,240,616 BI 6,245,537 BI 6,251,920 BI 6,254,632 B 6,254,634 111 6,258,121 BI 6,268,390 B1 6,273,913 B1 6,284,305 B1 6,287,320 B1 6,287,628 BI 6,299,604 BI 6,306,144 BI 6,306,166 Bl 6,306,176 BI 6,306,421 BI 6,309,380 BI 6,309,660 B1 6,313,264 BI 6,316,018 BI 6,335,029 B1 6,358,556 B1 6,369,039 B1 6,379,382 BI 6,387,121 BI 6,403,635 Bl 6,407,067 B1 6,517,858 BI 6,517,889 131 6,545,097 132 6,585,764 B2 6,620,194 B2 6,746,773 B2 6,776,796 B2 6,808.536 B2 200 1100 07 0 83 Al 2001/0029351 Al 200110029650 Al 200110032014 Al 200110034363 Al 200110037145 Al 200210010418 Al 2002/0032477 Al 2002/0041899 Al 200210061326 Al 200210068969 Al 2002!0071902 Al 200210082680 Al 2002/0082685 Al 200210091433 Al 200210095114 Al 200210099438 Al 2002/0103526 Al 200210119178 Al 2002/0 1 23 505 Al 2002/0127327 Al 200210133222 Al 200210133224 Al 200210165609 Al 20 0210 1 93 4 7 5 Al 20 03100 6 5 3 7 7 Al 200310216699 A 1 2004/0049265 Al 200410243097 Al 200410260268 Al 200510002986 At 2 0 0 5100 04 66 3 Al 2005/0033261 Al ........ 6041265 112001 Zhong .......... 2/2001 Clackson at al . ............. 514131 212001 Strecker .................... 62311.13 412001 Chudzik et M. 512001 Tang et al. ................. 5141523 612001 Yan 6/2001 Williams et al, ............ 4351135 612001 Grainger ct al . ............ 5141319 712001 Wu et al. 712001 Anderson et al........... 62311.42 712001 Yang at al. 712001 Kunz 812001 Wrigbt et al. 9/2001 Ding et al . ................ 42712.28 912001 Slepian 912001 Hossainy et al. 1012001 Ragheb et al. 1012001 Sydney et al ............... 6061108 1012001 Barry cc al. 1012001 Whitbourne 1012001 Kunz et al. 10!2001 Larson at al. 101200 Hsu et al. 1112001 Caggiano et al. 1112001 Ding et al . ................. 4241423 112002 Kamath at al . ............. 4241423 312002 Ding et al . ................ 42712.24 412002 Palasis et al ............... 424/93.2 412002 Yang ......................... 62311.42 512002 Alt ............................ 62311.15 612002 Kinsella at al. ............. 5141449 6/2002 Schafer ....................... 514119 212003 Le Mocl ct al ............. 424/424 212003 Jayarnman ................. 42712-24 412003 Pinchuk at al .............. 5257240 712003 Wright et al ............... 62311.42 912003 Ding et al . ................ 62311.43 612004 Llanos ct al ................ 4281421 8/2004 Falotico ct al ............. 62311.46 1012004 Wright ct al ............... 62311.42 712001 Roorda 1012001 Falotico et al...,..... 6041103.02 1012001 Johnson 1012001 Yang ct al. 1012001 Li at al. 1112001 Guruwaiya ct al. 112002 Lary et al .............. 6041101.04 312002 Helmus at al . .............. 62M.2 412002 Chudzik ct al . ............ 4241487 512002 Li et al . ..................... 4241424 612002 Sbanley at al ............. 623/1,16 6/2002 Ding cc al . ................ 42712.24 612002 Shanlcy cc al, - .......... 62311.16 6/2002 Sirhan at al. .............. 62311.42 712002 Ding at al . .................. 62311.2 712002 Palasis .................... 604196.01 712002 Furst ......................... 62311.16 812002 Steinke ...................... 62311.11 812002 Levesque et al............ 4241423 912002 Mollison et al ............. 5141291 912002 Schwartz at al. .......... 42712.15 912002 Das ........................... 623/1.16 912002 Bajgar et al, -.- ......... 623/1.39 11/2002 Llanos .......................6041500 1212002 Hossruny et al. ........... 5241113 412003 Davila et al . ............... 6041265 1112003 Falotico 312004 Ding at al . ................ 62311.42 1212004 Falotico at al .............. 604/5011 1212004 Falotico et al. ............. 6041500 112005 Falotico et al .............. 4241426 112005 U.mos ct a] ............... 62311.46 212005 Falotico et al .............. 604/500

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 19 of 38

US 7,300,662 B2
Page 5
200510106210 200510187611 200510208200 200610088654 200610089705 Al Al Al Al Al 512005 812005 912005 412006 412006 Ding ct al . ................. 4241423 Ding et al . ................ 62311.15 Ding e; at . ................ 42712.25 Ding et al . ................ 42712.21 Ding et al . ................ 62311.15 WO WO WO WO WO WO WO WO WO 01/87372 At 01187373 At WO 01187376 Al 02/26139 Al 02/26271 Al 02/26280 Al 02/26281 Al 03/015664 Al 0 3105 7 2 1 8 Al 1112001 1112001 1112001 412002 412002 412002 412002 2/2003 712003

FOREIGN PATENT DOCUMENTS DE EP EP EP EP EP EP EP EP EP EP EP EP EP EP EP EP 19723723 Al 0 145 166 A2 0 177 330 A2 0 183 372 Al 0 221 570 A2 0 421 729 A2 0 540 290 A2 0 568 310 Al 0 604 022 Al 0 621 015 Al 0 623 354 Al 0 734 698 A2 0 712 615 Al 0 716 836 Al 0 800 801 Al 0 734 721 Al 0 747 069 A2 0 761 251 Al 0 830 853 Al 0 540 290 B1 0 815 803 Al 0 850 651 A2 0 938 878 A3 0950386 B1 0 968 688 Al 0 633 032 BI 1 192 957 A2 1 588 726 Al 1 588 727 Al 0 566 807 Al 1 205 743 2 135 585 A 0 662 307 A2 660689 1457921 89103232 Al WO 91112779 Al WO 92/15286 Al WO 94101056 Al WO 94121308 Al WO 94121349 Al WO 94/24961 Al WO 96100272 Al WO 96126689 Al WO 96132907 Al WO 96134580 Al 96141807 Al WO 97125000 Al WO 97133534 Al 97135575 Al 98108463 Al WO 98113344 Al WO 98/19628 Al 98/23244 Al WO 98/23228 Al WO 98134669 At WO 98136784 Al WO 98147447 At WO 98156312 Al 00121584 Al 00/27455 Al WO 00127445 Al 00132255 Al 00138754 Al 01187342 A2 1211998 611985 911986 611986 511987 411991 1011992 1111993 611994 1011994 1111994 311996 5/1996 611996 811996 1011996 1211996 311997 711997 111998 711998 711998 911999 1011999 112000 212001 412002 1012005 1012005 411992 911970 911984 1211994 511979 211989 411989 911991 911992 111994 911994 911994 1111994 111996 911996 1011996 1111996 1211996 711997 911997 1011997 311998 411998 511998 611998 611998 811998 811998 1011998 1211998 412000 512000 512000 612000 712000 11/2001

OTHER PUBLICATIONS
U.S. Appl. No. 071819,314 , filed Jan . 9, 1992, Morris. U.S. Appl. No. 081424, 884, filed Apr. 19, 1995, Helmus et at. U.S. Appl. No. 061526,273, filed Sep. 11, 1995, Ding. U.S. Appl. No. 081730 ,542, filed Oct . 11, 1996, Helmus. U.S. Appl. No. 091575,480, filed May 19, 2000, Kopia. U.S. Appl. No. 101431,059, filed May 7, 2003, Falodco. Abraham, IL T., "Mammalian target of rapamycin : Immunosupressivc drugs offer new insight into cell growth regulation , " Progress in k#Lmmation Research , 2000, Switzerland. Alvarado, R. et al., "Evaluation of Polymer-coated Balloon -expandable Stents in Bile Ducts," Radiology, 1989, 170, 975-978. Badimon, J . J. et al., "Inhibitory Effects of Rapamycin on Intimal Hyperplasia Alter PTCA," JACC, Mar. 1998. Bailey et al ., "Polymer Coating of Palmaz-Schatz Stent Attenuates Vascular Spasm after Stent Placement," Circulation , 82:I11-541 (1990). Berk, B . C. et ;it., "Pharmacologic Roles of Heparin and Gucocorticoids to Prevent Restenosis After Coronary Angioplasty," J9CC, May 1991, 17(6), IIIB-11713. Bertram, P. G. et al ., " The 14-3-3 proteins positively regulate rapamycin- sensitive signaling," Current Biology, 1998 , 8, 12591267. Biomaterials Science (B.D. Ratner, Ed .), Academic Press, New York, NY, pp. 228-238, 1996. Campbell, G . R. et al., "Phenotypic Modulation of Smooth Muscle Cells in Primary Culture, Vascular Smooth Muscle Cells in Culture;" CRC Press, 1987, 39-55. Chang, M. W. ct al., "Adcnovirus -mediated Over -expression of the Cyclin/Cyclin -dependent Kinase inhibitor, p21 inhibits Vascular Smooth Muscle Cell Proliferation and Neointima Formation in the Rat Carotid Artery Model of Balloon Angioplasty," J. Chn, hivest., 1995, 96, 2260-2268. Chung, J . et al., " Rapamycin -FKBP specifically blocks growthdependent activation of and signaling; by the 70 kd S6 protein kinases," Cell, Jun. 26, 1992, 69(7), 1227-1236. Clowes, A. W. ct al., "Kinetics of cellular proliferation aflcr arterial injury. IV. Heparin inhibits tat smooth muscle mitogcnesis and migration," Circ. Res., 1986, 58(6), 839-845. Clowes, A. W. et a ., Kinetics of Cellular Proliferation after Arterial Injury, Laboratory Investigation , 1985, 52(6), 611.616. Clowes, A. W. ct al., " Significance of quiescent smooth muscle migration in the injured rat carotid artery," Circ Rec. 1985, 56(1), 139-145. Clowes, A. W., "Suppression by heparin of smooth muscle cell proliferation in injured arteries,"Natwr, 1977,265(5595),625-626. Colbum, M. D. ct al ., "Dose responsive suppression of myointimal hypcrplasia by dexnmcthasone," J Yasc Srug., 1992, 15, 510-518. Currier, J. W. et it ., "Colchicinc Inhibits Rcstcnosis Aflcr Iliac Angioplasty in the Atherosclerotic Rabbit," Circ., 1989, 80(4), 11-66 (Abstract No. 0263). Encyclopedia of Polymer Science and Engineering , vol. 7, Fluocoearbon Elastomers , p. 257-267, Mar. 1989. Farb, A. ct al., "Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein ," Circ. Res., 1997, 80, 542-550. Ferns, G. A. A. ct al., " Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF;" Science, 1991, 253, 1129-1132.

EP
EP EP EP EP EP EP EP EP EP EP EP FR GB GB GB SU SU WO WO WO WO WO WO WO WO WO

WO
WO WO WO WO WO WO

WO
WO

WO
WO WO WO WO Wo WO WO WO WO WO WO

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 20 of 38

US 7,300,562 B2
Page 6

Fischman, D. L. et al., "A Randomized Comparison of CoronaryStent Placement and Balloon Angioplasty in the Treatment of Coronary Axlery Disease," N. Eng. J. Afed., Aug. 25, 1994, 331(8), 496-501, Franklin, S. M. et al., "Pharmacologic prevention of restenosis alter coronary angioplasty; review of the randomized clinical trials," Coronary Artery Disease Mar. 1993, 4(3), 232-242. Fukuyarna, J. ct al., "Tranilast suppresses the vascular intimal hyperpla_sia after balloon injury in rabbits fed on a high-cholesterol diet," Eur. J. Pharmacol., 1996, 318, 327.332. Gregory, C. R, et al., "Rapamycin Inhibits Arterial Intimal Thick. ening Caused by Both Allo immune and Mechanical Injury," Trartsplarrrarion, Jun. 1993, 55(6), 1409-1418. Gregory, C. R. et al, "Treatment with Rapamycin and Mycophenolic Acid Reduces Arterial Intimal Thickening Produced by Mechanical Injury and Allows Endothelial Replacement," Transplantation, Mar. 15, 1995, 59(5), 655-661. Guyton, J. R_ el a1 ., "Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin;" Circ. Res., 1980, 46, 625.634. liansson, G. K. et al., "Interferon-y Inhibits Arterial Stenosis After Injury," Circ., 1991, 84, 1266-1272. Hnshemolhosseini, S. et al., "Rapamycin Inhibition of the GI to S Transition Is Mediated by Effects on Cyclin D1 mRNA and Protein Stability," J. Biol Chenr, Jun. 5, 1998, 273, 14424-14429. Jonasson, J. Lt al., "Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury," Proc. Natl., Acad. Sel., 1988, 85, 2303-2306. Kuhnt, M. et al., "Microbial Conversion of Rapamycin," Enzyme and Alicrobial Technology, 1997, 21, 405412. Lange, R. A. MD ct al., "Reslenosis After Coronary Balloon Angioplasty," Anna Rev Wed., 1991, 42, 127-132. Liu, M. W. ct al., "Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit," Circ., 1990, 81, 10891093. Liu, M. W., MD et al., "Restenosis After Coronary Angioplasty Potential Biologic Determinants and Role of Intimal Hyperplasia," Circulation, 1989, 79, 1374-1387. Lundergan, C. F. ct al., "Peptide inhibition of Myointimal Proliferation by Angiopeptin, a Somatostatin Astaloguc," JACC, May 1991, 17(6), 132E-1368. Majesky, M. W. ct al., " Heparin regulates smooth muscle S phase entry in the injured rat carotid artery," Cire. Res., 1987,61,296-300. Marx, S. O. et al., "Rapamycin-rYBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells," Circ. Res., 1995, 76, 412417. Nemeeek, G. M. ct al., "Terbinaftne Inhibits the Mitogenic Response to Platelet-Derived Growth Factor in Vitro and Neoinimal Proliferation in Vivo," J. Pharmacol. Exp, Aera., 1989, 248, 1167-1174. Okada, T. ct al., "Localized Release ofPcrivascularHeparin Inhibits Intmal Proliferation alter Endothelial Injury without Systemic Anticoagulation," Neurosurgery, 1989, 25, 892-898. Poon, M, et al., "Rapamycin Inhibits Vascular Smooth Muscle Cell Migration;" J. Clin Invest., Nov. 1996, 98(10), 2277-2283. Popma, J. J. et al., "Clinical trials of restenosis after coronary angioplasty " Cirnrlation, Sep. 1991, 84(3), 1426-1436. Powell, J. S. at al ., "Inhibitors of Angiotcasin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury," Science, 1989, 245, 186-188. Rensing, B . J. et al., Coronary restenosis elimination with a sirolmus cluting stent, European Heart Journal, 2001, 22, 21252130. Rodtck, C, et al., "Methods for the Transcervical Collection of Fetal Cells During the First Trimester of Pregnancy;" Prenatal Diagnosis, 1995, 15, 933-942. Scrruys, P. W. et al., "A comparison of balloon -exp,vtdabte-stent implantation with balloon angioplasty in patients with coronary artery disease," NEngl JAfed, Aug. 25, 1994; 33](8), 489495. Serruys, P, W. ct al., "Evaluation of ketanscrin in the prevention of restenosis after percutancous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial," Circularion. Oct. 1993; 88(4 Pt 1), 1588-1601.

Serruys, P. W. et al., " Heparin-coated Palmaz-Schatz stents in human coronary arteries . Early outcome of the Benestent-]I Pilot Study" Circulation, Feb. 1, 1996; 93(3), 412.422. Sickierka, J. J., "Probing T-Cell Signal Transduction Pathways with the ]mmunosupressive Drugs, FK-506 and Rapamycin," Immunologic Research, 1994, 13, 110-116. Sigwart, et al., "Intravascular Sleets to Prevent Occlusion and Rcstenosis After Transluminal Angioplasty," N, E,rgl, J,, bled., Mar. 19, 1987, 316, 701-706. Simons, M. et al., "Antisense c-niyb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo," Nature, 1992, 359,67-70, Snow, A. D, et al., "Heparin modulates the composition of the extracellular matrix domain surrounding arterial smooth moscle cells," Am. J. Pathol., 1990, 137, 313-330. Sollott, S. J. et al ., "Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat," J Clin. Invest., 1995, 95, 1869.1876. van Der Giessen , et al., "Self-expandable Mesh Scents : an Experimental Study Comparing Polymer Coated and Uncoated Wallstent Stents in the Coronary Circulation of Pigs," Circulation 1990, 82(suppl . 111):111-542, van Der Giessen , W, J, et al., "Coronary scenting with polymercoated and uncoated sel f-expanding endoprostheses in pigs," Coron. Art, Disease 992; 3, 631-640. Vasey, C. G. ct a., "Clinical Cardiology: Stress Echo and Coronary F'low", , Circularlon, Oct. 1989, 80 (4) Supplement 11, 11-66. Verweire, E. et al., "Evaluation of Fluorinated Polymers As Coronary Stent Coating," Journal of lfarerials Science. Afarerials in medicine, Apr. 2000. Weinberger, J. et al., "Intracoronary irradiation: dose response for the prevention of restenosis in swine, " Int. J. Rad Out. BioL PhJs., 1996, 36, 767-775. Preliminary Amendment in U.S. Appl. No. 071258,189, May 22, 1989. Trial Transcript from Nov. 6, 2000 al 185-90 and 235-36 (Attorncy's opening remarks regarding ' 984 patent). Trial Transcript from Nov, 7, 2000 at 274-301, 307.315, 320-28 and 332 (Cordis expert testimony regarding the Palmaz-Schatz stcnt); 370-379, 480-496 (J. Pah7w testimony regarding the PalmazSchatz stmt, the '984 patent and the connected z-stmt art). Trial Transcript from Nov. 8, 2000 at 547-63, 657-63, 674-722, 782.85 (Cordis experttestimony regarding the Palmaz-Schatz stent, the '984 patent and the connected z-stent art). Trial Transcript from Nov. 9, 2000 at 819-23, 921 (Gordis expert testimony regarding the '984 patent ); 926.941 . (R. Croce testimony re Palmaz-Schatz stem); 1033.1053. (R, Schatz testimony). Trial Transcript from Nov, 13, 2000 at 1086-1134. (R. Schatz testimony); 1275-1305 (Cordis expert testimony regarding the '984 patent). Trial Transcript from Nov, 14, 2000 at 1390-1404, 1448-1454, 1486.1500 (Cordis expert testimony regarding the '984 patent). Trial Transcript from Nov. 15, 2000 at 1686 -87, 1724-42, 1828-341 1850-54, 1887-92 (AVE expert testimony regarding the '984 patent). Trial Transcript from Nov. 16, 2000 at 2077-198 (AVE expert testimony regarding the alleged obviousness of the '984 patent). Trial Transcript from Nov. 17, 2000 at 2331-34 (jury instructions as to the meaning of the limitations of the claims of the '984 patent). Trial Tmscript from Nov. 20, 2000 at 2441.48, 2499-2500, 254650, 2552.56 (Attorney's closing arguments regarding the '984 patent), Trial Transcript from Nov. 21, 2000 at 2592-94 (reading of jury verdict), Trial Transcript from Dec. 18, 2000 at 2750-95 (Cordis expert testimony regarding the Palmaz-Schatz stent during the damages phase). Trial Transcript from Dec. 20, 2000 at 3421-88 (AVE expert testimony regarding the Palmaz-Schatz stmt during the damages phase). Jury verdict, dated Nov. 21, 2000. District Court decisions on post-trial motions (194 F. Supp. 2d 323). Court of Appeal for the Federal Circuit decision (339 F.3d 1352).

Case 1:07-cv-00765-SLR

Document 7-3

Filed 12/10/2007

Page 21 of 38

US 7,300,662 B2
Page 7
Trial Transcript from Mar. 4, 2005 at 133-135, 171-173 and 192-96 (Attorney's opening remarks regarding '984 validity). Trial Transcript from Mar. 7, 2005 at 275-31 1 (Cordis expert testimony regarding the Palmaz- Schatz stent); 34246, 353-59, 416425 (J. Palmaz testimony regarding the Palmaz-Schatz stair[, the '984 patent and the connected z-scent art ), 430449, 452-58, 462492 ( R. Croce testimony regarding the Palmaz-Schatz slant); 500.507 (Cordis e xpert testimony regarding the '994 patent). Trial Transcript from Mar. 8, 2005 at 609 (Cordis expert testimony regarding the '984 patent); 628-73, 724-740, 773, 801-839 (Cordis expert testimony regarding the '984 patent , the prior art and the Palmaz-Schatz stent). Trial Transcript from Mar. 9, 2005 at 93649, 968.69 (Cordis expert testimony regarding the '984 patent , the prior art and the PalmazSchatz slant). Trial Transcript from Mar. 10, 2005 at 1427-74, 178-1509, 1514-23 (AVE expert testimony regarding the alleged obviousness of the '984 patent); 1566-93 (AVE expert testimony regarding PalmazSchatz stent ); 1634-49 ( R. Schatz testimony). Trial Transcript from Mar, 11, 2005 at 184647, 1891-1900, 1919 (Attorneys ' closing arguments regarding ' 984 obviousness). Trial Transcript from Mar. 14, 2005 at 1964-67 (reading of jury verdict). Jury verdict dated Mar. 14, 2005. Medtronic Vascular Inc.'s Opening Brief in Support of Its Motion for Judgment As A Infringement Claim dated Apr. 19, 2005. Medtronic Vascular Inc.'s Opening Brief in Support of Its Motion for a New Trial dated Apr. 19, 2005. D.J. 1407, Cordis' Combined Answering Brief In Opposition to AV E's Motion for 1MOL on Infringement of the Palmaz '762 and Schatz '984 Patents and Its Motion for a New Trial dated May 5, 2005. D.I. 1414, Medtronic Vascular Inc.'s Combined Reply Brief In Support of Its Motion for Judgment as a Matter of Law on Cordis Corp .' s Patent Infringement Claims and Its Motion for a New Trial dated May 19, 2005. Trial Transcript from Feb. 8, 2001 at 372-412, 449469 (B. Tabor testimony regarding the prosecution of the '417, '984 and '332 patents); 510-13 (J. Milnamow testimony regarding the prosecution of the '332 patent); 558-604 (J. Palmaz testimony regarding the prosecution of the '417, '984 and '332 patents and the prior art). Trial Transcript from Feb. 9, 2001 at 63745, 662-672, 682-85 (J. Palmaz testimony regarding the prior art); 699-742 (R. Schatz testimony); 769-770 , 790-95 (Cordis expert testimony regarding prior art). D.I. 1067, Medtronic AVE, Inc.'s Post-Trial Brief Relating to the Unenforceability of the '762 and '984 Patents Due to Inequitable Conduct. D.I. 1077, Gordis ' Combined Answering Brief in Opposition to AVE's BSC's Post-hearing Briefs on Alleged Inequitable Conduct Concerning the '762, '984 and '332 Patents. D.I. 1089, Reply Brief In Support of Medtronic AVE, Inc.'s Contention that the '762 and ' 984 Patents are Unenforceable Due to inequitable Conduct dated May 7, 2001. C.A. No. 00.886-SLR, Answer and Counterclaims of Def. Medtronic AVE, Inc. To First Amended Complaint of Plaintiff Cordis Corp. BSC's Opening Past-Trial Brief in Support of Its Defense That the Patents in Suit Are Unenforceable, dated Mar. 16, 2001. Reply Brief in Support of BSC ' s Defense That the Patents in Suit Are Unenforceable, dated May 7, 2001. Court's Decision on allegations of inequitable conduct ( 194 F. Supp. 2d 323) Mar. 28, 2002. Trial Transcript from Nov. 21, 2000 at 155-57 and 180-84 (Attomcys'opening remarks regarding ' 332 patent). Trial Transcript from Nov. 27, 2000 at 227-51, 260.300 (Cordis expert testimony regarding the Palmaz·Schatz stent ); 343-60, 36367, 424-33 (J. Palmaz testimony regarding the Palmaz-Schatz atent and the '332 patent). Trial Transcript from Nov. 28, 2000 at 649-7 t. Trial Transcript from Nov. 29, 2000 at 791-816, 859-870, 953-62 (Cordis expert testimony regarding the '332 patent and the PalmazSchatz scent). Trial Transcript from Nov. 30, 2000 at 1018 (Cordis expert testimony regarding the '332 patent ); 1062.80, 1108-1111 (R. Croce testimony regarding the Palmaz-Schatz stent); 1169-70, 1205-17, 1236-45 ( Cordis expert testimony regarding the '332 patent). Trial Transcript from Dec. 1, 2000 at 1352-54 (Cordis expert testimony regarding the '332 patent ); 1364-1442 ( R. Schatz testimony); 1493-1508, 1552 -69 (BSC expert testimony regarding the '332 patent and the Palmaz -Schatz stent). Trial Transcript from Dec. 4, 2000 at 1602-12, 1638-51, 1713-14, 1730-61, 1811-14, 1823 -36 (BSC expert testimony regarding the alleged obviousness of the '332 patent , the prior art and the Palmaz-Schatz scent). Trial Transcript from Dec. 6, 2000 at 2318-27, 2342-58 (BSC expert testimony regarding the '332 patent).
Trial Transcript from Dec. 7, 2000 at 2549.52 (Cordis expert testimony regarding the '332 patent); 2575-2579, 2591-92, 2630· 31, 2649, 2669-71, 2684-85, 2688, 2708-10, 2725-27 (Attorney closing argument regarding '332 patent); 274246 Q'ury instructions as to the meaning of the limitations fo the claims of the '332 patent).

Trial Transcript from Dec. 11, 2000 at 2817-22 (reading ofjury verdict). Jury verdict, dated Dec. 11, 2000. D.I. 699, Motion by Defendant BSC and Scimed Life Systems, Inc. For Summary Judgment of Invalidity oU.S. Patent No. 5,902,332 dated Apr. 4, 2000. D.1.896, Order Denying Motion for Summary Judgment of Invalidity and Unenforceability of Claims 1, 3, and 5 of the U.S. Patent No. 5,902,332 Denying 1699-11 Motion for Summary Judgment of Invalidity of U.S. Patent No. 5,902,332 dated Oct. 12, 2000. Wright at al., Pcrcutaneous Endovascular Scent: An Experimental Study (Abstract), RSNA Meeting, (Nov. 28, 1984). Hearing Transcript from Feb. 10, 1998 at 122-32, 146-80 (Attorneys' opening remarks regarding '417 patent); 180-312 (11Schatz testimony) [ Portions of This Transcript Have Been Removed As Confidential]. Hearing Transcript from Feb. 11, 1998 at 427-575, 577-651 (Cordis expert testimony regarding the '417 patent , the prior art and the Palmaz-Schatz stent). Hearing Transcript from Feb . 13, 1998 at 1121-1261 (Guidant expert testimony regarding the alleged obviousness of the '417 patent, the prior art and the Palmaz-Schatz stent). [Portions of This Transcript Have Been Removed As Confidential]. Order by J. Robinson denying Cordis' Motion for a Preliminary Injunction Against ACS dated Jul. 17, 1998. ACS, Int.'s and Guidant Corp.'s Opening Brief in Support of Their Motion for Summary Judgment of Invalidity of U.S. Patent No. 5,102,417 dated Aug, 27, 1998. Plaintiffs' Answering Brief in Opposition to ACS' and BSC' Motion for Summary Judgment on Obviousness dated Sep . 2 4, 1998. Order dated Mar. 31, 2000. Schatz Deposition Testimony; May 15, 1996; 79-83, 89.92, 105-107 and 153-161.
Schatz Deposition Testimony ; May 16, 1996: 555-564, 569-572. Schatz Deposition Testimony; Jan . 18, 1998 : 67-73, 108-110. Schatz Deposition Testimony; Jul. 14, 1998: 69-77, 108-112, 119123.

Schatz Deposition Testimony ; Jul. 12, 1999 : 88-91, 132-135, 144149,218 -223, 231-242. Schatz Deposition Testimony; Jul. 13, 1999: 251-334, 339.345, 374416. Schatz Deposition Testimony; Jul. 14, 1999 : 454-550. Schatz Deposition Testimony ; Jul. 15, 1999: 560-614. Schatz Deposition Testimony; Dec. 2, 1999: 906-911, 928-942, 945.963,976-978, 1029-1034, 1038-1042. Palmaz Deposition Testimony, Nov. 5, 1991: 160.172. Palmaz Deposition Testimony, Feb. 5, 1995: 710-727. Palmaz Deposition Testimony, Jul. 16, 1998: 55-56; 81-82. Palmaz Deposition Testimony, Jul. 28, 1999: 560-568, 570-579. Palmaz Deposition Testim